CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 530 enrolled
Drug / intervention
Testing of BRCA status regarding germline and somatic mutationgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02222883
NCT02222883N/ACompleted
CompareCT.gov

Prevalence of BRCA in Patients With Primary or Platinum Sensitive Recurrent Ovarian Cancer.

AGO Research GmbH·observational·Posted Aug 21, 2014·Updated Jun 16, 2021

In Brief

An observational study evaluating Testing of BRCA status regarding germline and somatic mutation for BRCA Status and Ovarian Cancer. Completed, enrolled 530 participants across 20 sites.

Detailed Summary

The aim of this prospective registration and translational research study is to evaluate the praevalence of BRCA regarding germline and somatic mutations.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBRCA Status, Ovarian Cancer
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 21, 2014
Enrollment StartMar 1, 2015
Primary CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 11.9 years ago

Interventions

Testing of BRCA status regarding germline and somatic mutationgenetic